Pharmaceutical Executive December 29, 2025
Key Takeaways
- AstraZeneca plans a $570 million investment in Toronto to expand its clinical studies, highlighting Canada’s potential as a life sciences hub.
- Enhertu received FDA priority review for treating metastatic HER2-positive solid tumors, marking a potential first tumor-agnostic HER2-targeted medicine.
- AstraZeneca’s 2024 focus included expanding its business through 2030 with new treatments and regulatory approval in Japan for Voydeya, a PNH treatment.
Pharmaceutical Executive detail’s the company’s history at the healthcare conference.
While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.
2025
At the 2025 conference, the company detailed the company’s performance during the first three quarters of 2024. According to the CFO,...
Today's Sponsors
Today's Sponsor